Drug intelligence / Profile preview

Telzox

Development stage: Unknown
Lead developer: Lloyd Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Telzox is a generic formulation of telmisartan, a small molecule angiotensin II receptor blocker (ARB) developed and marketed by Lloyd Healthcare. It is primarily indicated for the management of hypertension (high blood pressure) and to reduce the risk of cardiovascular events such as myocardial infarction and stroke. Additionally, it is used in the management of diabetic nephropathy in patients with type 2 diabetes. Telzox works by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, leading to vasodilation and reduced aldosterone secretion.

Brand names: Telzox
Other names: telmisartan

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on Telzox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telzox.

Explore the full profile